Max Healthcare Navigates Oncology Drug Pricing Challenges, Forecasts Stronger Margins and Home Care Growth
Loading more articles...
Max Healthcare Flags Oncology Drug Pricing Strain, Anticipates Overall Margin Boost
C
CNBC TV18•10-02-2026, 14:55
Max Healthcare Flags Oncology Drug Pricing Strain, Anticipates Overall Margin Boost
•Max Healthcare expects a positive overall margin outlook despite mixed impacts from government healthcare scheme changes.
•The company has stopped supplying certain oncology drugs under government pricing rules due to cost economics, as prices are capped below procurement costs.
•Discussions are ongoing with the government to review the pricing framework for these drugs.
•Home healthcare and allied businesses are projected to continue growing at a 20-25% CAGR.
•Policy revisions under CGHS are expected to result in a net positive financial impact of approximately ₹140 crore for Max Healthcare.
